Effect of janus kinase inhibitors and methotrexate combination on malignancy in patients with rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials

BACKGROUND: Rheumatoid arthritis (RA) is a systemic autoimmune disease. The combination therapy of methotrexate (MTX) and Janus kinase inhibitor (JAKi) is commonly used. Patients with RA are at increased risk of malignancy, however, it remains unclear whether the combination therapy is associated wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Solipuram, Vinod, Mohan, Akhila, Patel, Roshniben, Ni, Ruoning
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8080865/
https://www.ncbi.nlm.nih.gov/pubmed/33910632
http://dx.doi.org/10.1186/s13317-021-00153-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8080865/
https://www.ncbi.nlm.nih.gov/pubmed/33910632
http://dx.doi.org/10.1186/s13317-021-00153-5

Ejemplares similares